Smart drug delivery system of nano-mebendazole medication, which depends on chitosan nanomolecule for murine trichinellosis treatment

[Display omitted] •Self assembly design nanocomposite on Cs/MBZ with ZnO NPs.•Loading and release process of MBZ from the nanocomposite surface.•Antioxidant activity of the modified MBZ drug.•Modified MBZ drug for murine trichinellosis treatment. The primary objective of this study is to formulate a medication system for mebendazole (MBZ) as an antiparasitic agent by the nanocomposite self-assembly of MBZ with the surface of nanochitosan (Cs) and zinc oxide nanoparticles (ZnO NPs). The nanocomposite (Cs@MBZ.ZnO) was synthesized using the precipitation method, and characterization procedures were employed to assess the enhanced therapeutic efficacy for treating trichinellids. The stability, distribution, and long-term electrochemical characteristics, resulting in a cycle stability of 79 %. The MBZ loaded with Cs NPs surface, whose incorporation capacity was recorded at 58.7 %, while the release efficiency was displayed at 77 % after 96 h at pH 7.4. Sixty male Swiss albino mice were divided into six groups to illustrate the effect of the efficiency of the modified drug Cs@MBZ.ZnO. Biochemical tests AST, ALT, and globulin were performed, and it showed that the infected control group had significantly higher levels, while all treated groups had lower levels. The analysis of adult worm counts across all treated groups indicated the most significant reduction (96.4 %) in groups G5 and G6. Groups G5 and G6 showed minimal expression of VEGF in the intestinal tissue compared to the control group. The results encourage the use of the modified MBZ medication as an alternative MBZ drug, but the results need clinical trials to approve it.